Business Wire

VECIMA-NETWORKS

17.5.2023 14:16:25 CEST | Business Wire | Press release

Share
Vecima to Highlight 10G Access and Next-Generation Video Solutions at ANGA COM 2023

Vecima Networks Inc. (TSX: VCM) will showcase industry leadership at ANGA COM 2023, with technology demonstrations and panel presentations highlighting 10G PON fiber access solutions, Remote PHY (R-PHY) and Remote MACPHY (R-MACPHY) solutions, and next-generation video solutions, including Open CDN and Dynamic Content.

Technologies to be on display

Named by Dell’Oro Group as the global market share leader for Remote Optical Line Terminals (OLTs), Vecima expands its fiber access portfolio with a flexible, compact, and powerful shelf-based platform that supports all predominantly deployed Passive Optical Network (PON) variants. The Entra® EXS1610 All-PON™ Shelf allows customers to selectively deploy Distributed Access Architecture (DAA) and fiber to the home in any market or hub deployment, allowing maximum flexibility to deploy Cable Access and Fiber Access solutions based on specific subscriber need.

The Entra® EN2112 R-PHY Access Node is a high-density, compact, two-port node that’s interoperable with third-party converged cable access platform (CCAP) cores and vCMTS (virtual cable modem termination systems), creating an open, flexible DAA ecosystem. Supporting architectures that push fiber deeper into the network, the EN2112 allows operators to optimize existing hybrid fiber-coax (HFC) network capacity and deliver increased bandwidth to subscribers. Vecima recently announced that Kbro, Taiwan’s largest cable operator, selected the EN2112 R-PHY Node as part of its DAA solution to enable high-speed DOCSIS® 3.1 services for its subscribers.

The Entra® ERM3 Remote PHY Device (RPD) is designed to easily upgrade existing HFC nodes to DAA, reduce installation time, and lower operating costs for service providers while dramatically increasing broadband capacity. The ERM3 RPD boasts a unique form factor and features, highlighting Vecima’s open and interoperable approach to hardware and software. Like all RPDs in Vecima’s lineup, the ERM3 is interoperable with vCMTS and third-party CCAP cores. Vecima recently announced Charter Communications selected the ERM3 to enable 10G services over HFC networks.

The Entra® SC-1D Entra Access Node offers a Remote MACPHY/R-MACPHY Device in a compact, European form factor. Part of Vecima’s DAA solution that’s deployed in Europe, the SC-1D enables operators to deploy gigabit broadband and new services to residential subscribers and businesses. In addition, moving to DAA delivers sustainability through digitization, enabling substantial energy savings. Dell’Oro Group recently named Vecima as the global revenue share leader in Remote MACPHY devices.

Vecima’s MediaScale™ Streaming solutions, including Open CDN for high-quality, congestion-free streaming that’s more cost-effective and efficient, and Dynamic Content with Ad Insertion for highly targeted ads and more value per impression.

MediaScale Open CDN can be provisioned via Open Caching APIs to deliver and cache video content on behalf of the provisioning upstream provider’s content delivery network. It helps service providers monetize the terabytes of internet traffic delivered free of charge today and prepare their networks for the petabytes of content yet to come. The subscriber gets an improved viewing experience, without the headache of rebuffering and poor video quality.

Service providers can gain control over content with the MediaScale Dynamic Content solution which supports content rights, blackouts, and advertising. By manipulating content at the edge of the network, operators can deliver more efficient, personalized video content and more opportunities to monetize that content with targeted, higher-value ads.

Vecima speakers at ANGA COM

Vecima’s Chris Busch, Principal Architect Office of CTO, will speak on “Fiber Access and Measuring QoE – Taking a Slice of the Access Network” on Wednesday, May 24.

Quotes from Vecima executives attending ANGA COM

“Operators in the region need flexibility as they expand their networks and plan for future services, and Vecima’s portfolio provides multiple options to get to 10G,” said John Ruwe, Vice President of EMEA Sales at Vecima. “Vecima continues to increase our footprint in the European market, and we look forward to showcasing our technology leadership at ANGA COM.”

“Vecima is helping operators around the world evolve their networks with 10G-capable fiber and cable access solutions that prime them for future growth,” said Clay McCreery, Chief Operating Officer at Vecima. “We’re leading the way in delivering limitless broadband connectivity and content-rich video experiences across Europe and around the world.”

Visit Vecima Networks at ANGA COM 2023
May 23-25 in Cologne, Germany
Koelnmesse Hall 8, Stand D40

To schedule a meeting with the Vecima team, contact us at sales@vecima.com.
Media and industry analysts, please contact bernadette.dunn@vecima.com.

About Vecima Networks
Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multigigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive.
Learn more at vecima.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005294/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye